Skip to main content

European Union Extends Review of Agilent, Varian Deal

NEW YORK (GenomeWeb News) – European Union regulators have extended their review deadline to Jan. 20 from the previous Jan. 6 on the proposed acquisition of Varian by Agilent Technologies.

According to a Reuters report today, EU regulators extended the deadline to make a decision on the deal after Agilent agreed to remedies for competition concerns. Those remedies were not specified, and Agilent officials did not return a call seeking comment before this article was published.

Agilent had reached an agreement in July to acquire Varian for around $1.5 billion. The firms said at the time that they expected to close the deal before the end of this year.

In September, the US Federal Trade Commission asked Varian and Agilent for additional information in connection with the proposed merger.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.